Table 1.
Description of total cohort and those testing interferon gamma release assay-positive.
| Variable | Total screened cohort [n (%)] | Proportion IGRA-positive [x/n (%)] | ||
| Total | 1053 | (100) | 118/1053 | (11.2) |
| Median age at IGRA test, years (IQR) | 42 | (36–49) | 42 | (38–48) |
| Year of HIV diagnosis | ||||
| 1985–1989 | 8 | (0.8) | 2/8 | (25.0) |
| 1990–1999 | 68 | (6.5) | 3/68 | (4.4) |
| 2000–2009 | 604 | (57.4) | 74/604 | (12.3) |
| 2010–2017a | 373 | (35.4) | 39/373 | (10.5) |
| Year of IGRA test | ||||
| 2014 | 393 | (37.3) | 43/393 | (10.9) |
| 2015 | 358 | (34.0) | 47/358 | (13.1) |
| 2016 | 147 | (14.0) | 18/147 | (12.2) |
| 2017 | 125 | (11.9) | 8/125 | (6.4) |
| 2018 | 24 | (2.3) | 2/24 | (8.3) |
| 2019 | 3 | (0.3) | 0/3 | (0.0) |
| 220 | 1 | (0.1) | 0/1 | (0.0) |
| 2021b | 2 | (0.2) | 0/2 | (0.0) |
| Sex | ||||
| Male | 597 | (56.7) | 53/597 | (8.9) |
| Female | 456 | (43.3) | 65/456 | (14.3) |
| CD4+ cell count at IGRA testing (cells/μl) | ||||
| Median (IQR) | 530 | (380–700) | 545 | (440–720) |
| Range | 10–2260 | 90–1350 | ||
| ≤200 | 48 | (4.6) | 2/48 | (4.2) |
| 201–350 | 181 | (17.2) | 12/181 | (6.6) |
| 351–500 | 250 | (23.7) | 36/250 | (14.4) |
| >500 | 574 | (54.5) | 68/574 | (11.8) |
| Ethnicity | ||||
| Black African | 498 | (47.3) | 90/498 | (18.1) |
| South Asian | 94 | (8.9) | 17/94 | (18.1) |
| White | 388 | (36.8) | 9/388 | (2.3) |
| Mixed | 16 | (1.5) | 0/16 | (0.0) |
| Black Caribbean | 14 | (1.3) | 0/14 | (0.0) |
| Black other | 10 | (0.9) | 0/10 | (0.0) |
| Other | 32 | (3.0) | 2/32 | (6.3) |
| Unknown | 1 | (0.1) | 0/1 | (0.0) |
| UK birth status | ||||
| UK born | 361 | (34.3) | 10/361 | (2.8) |
| Non-UK born | 692 | (65.7) | 108/692 | (15.6) |
| Region of birth | ||||
| Sub-Saharan Africa | 538 | (51.1) | 96/538 | (17.8) |
| South Asia | 50 | (4.7) | 8/50 | (16) |
| Europe and Central Asia | 421 | (40.0) | 12/421 | (2.9) |
| East Asia and Pacific | 22 | (2.1) | 2/22 | (9.1) |
| Latin America and Caribbean | 13 | (1.2) | 0/13 | (0.0) |
| Middle East and North Africa | 5 | (0.5) | 0/5 | (0.0) |
| North America | 4 | (0.4) | 0/4 | (0.0) |
| TB incidence in country-of-birth | ||||
| <50/100 000 population | 439 | (41.7) | 12/439 | (2.7) |
| 50–149/100 000 population | 58 | (5.5) | 12/58 | (20.7) |
| 150–249/100 000 population | 427 | (40.6) | 74/427 | (17.3) |
| 250–349/100 000 population | 63 | (6.0) | 11/63 | (17.5 |
| ≥350/100 000 population | 66 | (6.3) | 9/66 | (13.6) |
| Type of IGRA performed | ||||
| QuantiFERON-TB testc only | 1013 | (96.2) | 115/1013 | (11.4) |
| QuantiFERON-TB testsc and T- SPOT.TB | 25 | (2.4) | 2/25 | (8) |
| T-SPOT.TB only | 15 | (1.4) | 1/15 | (6.7) |
IGRA, interferon gamma release assay; IQR, interquartile range.
a
Individuals were included up and including to 30 June 2017.
b
30 June 2021 was used as the cut-off for following up patients for IGRA testing.
c
QuantiFERON-TB GIT or QuantiFERON-TB Plus.